Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery

Rhea-AI Summary

Hoth Therapeutics (NASDAQ: HOTH) announced deployment of OpenClaw™, an AI-enabled computational platform to accelerate drug discovery across its pipeline.

OpenClaw™ centralizes preclinical and clinical data in real time, standardizes workflows across dermatology, oncology and inflammatory programs, and is designed to speed candidate selection and increase probability of technical success, the company said.

News Market Reaction – HOTH

-6.65%

5 alerts

-6.65% News Effect

-13.2% Trough in 5 hr 13 min

-$993K Valuation Impact

$13.94M Market Cap

0.7x Rel. Volume

On the day this news was published, HOTH declined 6.65%, reflecting a notable negative market reaction. Argus tracked a trough of -13.2% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $993K from the company's valuation, bringing the market cap to $13.94M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $0.8056 Vol: Volume 100,590 vs 20-day ...

low vol

$0.8056 Last Close

Volume Volume 100,590 vs 20-day average 428,215 (about 0.23x typical activity). low

Technical Shares at 0.8987, trading below 200-day MA at 1.24, indicating a longer-term downtrend pre-announcement.

Peers on Argus

Momentum scanner shows 3 biotech peers moving up with median gains near 6.7%, wh...

3 Up 1 Down

Momentum scanner shows 3 biotech peers moving up with median gains near 6.7%, while 1 is down. This supports a broader sector tailwind alongside HOTH’s AI platform news.

Previous AI Reports

5 past events · Latest: Mar 04 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 04	AI for HT-KIT	Positive	+3.3%	Deployed OpenAI API to advance orphan HT-KIT toward IND and Phase 1.
Nov 20	NVIDIA program win	Positive	-10.4%	Accepted into NVIDIA Connect Program to expand GPU-accelerated AI capabilities.
Oct 08	NVIDIA AI licenses	Positive	+3.3%	Secured NVIDIA AI Enterprise licenses to power ML and neural network modeling.
Sep 04	PredictBBB.ai adoption	Positive	+0.8%	Adopted PredictBBB.ai (94% accuracy) to assess blood–brain barrier permeability.
Mar 27	AI obesity discovery	Positive	-7.4%	Merveille.ai subsidiary advanced AI-driven discovery for obesity treatment.

Pattern Detected

AI-related announcements have been generally positive but produced mixed stock reactions, with 3 aligned moves and 2 negative divergences.

Recent Company History

Over the past two years, Hoth has steadily expanded its AI capabilities, from adopting Lantern Pharma’s PredictBBB.ai platform and NVIDIA AI Enterprise infrastructure to joining the NVIDIA Connect Program and deploying the OpenAI API for HT-KIT. These steps consistently framed AI as a core R&D accelerator across programs such as HT-001, HT-KIT, and metabolic and CNS initiatives. Today’s OpenClaw™ deployment continues that trajectory by centralizing AI-enabled analytics across preclinical and clinical datasets.

Historical Comparison

-2.1% avg move · Across 5 prior AI-tagged releases, HOTH’s average 24-hour move was -2.09%, showing that positive AI ...

AI

-2.1%

Average Historical Move AI

Across 5 prior AI-tagged releases, HOTH’s average 24-hour move was -2.09%, showing that positive AI updates have not always translated into sustained upside.

AI usage has progressed from targeted tools (PredictBBB.ai, OpenAI API) and NVIDIA infrastructure toward broader, centralized AI platforms applied across multiple pipeline programs.

Regulatory & Risk Context

Active S-3 Shelf · $50 million

Shelf Active

Active S-3 Shelf Registration 2025-11-14

$50 million registered capacity

An effective Form S-3 shelf filed on 2025-11-14 permits up to $50 million in primary securities plus resale of 1,279,587 shares, giving Hoth flexibility to raise capital via common or preferred stock, debt, warrants, subscription rights, or units over the shelf’s term.

Market Pulse Summary

The stock moved -6.7% in the session following this news. A negative reaction despite strategic AI p...

Analysis

The stock moved -6.7% in the session following this news. A negative reaction despite strategic AI positioning would fit a history where AI-tagged news showed an average -2.09% one-day move and two prior negative divergences. The market may have discounted platform announcements until they translate into trial outcomes or partnerships. Any weakness could also reflect broader financing overhang, given an S-3 shelf of up to $50 million, and the stock’s position below its 200-day moving average before this release.

Key Terms

preclinical, clinical, dermatology, oncology, +3 more

7 terms

preclinical medical

"capable of integrating preclinical and clinical datasets in real time"

Preclinical describes the stage of drug or medical-product development when researchers test a candidate in the lab and in animals to see if it is safe, reaches intended targets, and shows basic effectiveness before any human trials begin. For investors, preclinical status signals an early, higher‑risk opportunity where positive lab results can increase value but significant work, time, and regulatory hurdles remain — like proofing a prototype in a workshop before road testing.

clinical medical

"capable of integrating preclinical and clinical datasets in real time"

Clinical describes activities, data, or findings that come from testing in humans or from direct patient care—examples include clinical trials, medical exams, and treatment outcomes. For investors, “clinical” signals evidence about a drug or device’s real-world safety and effectiveness; strong clinical results can increase the odds of regulatory approval and future sales, while negative clinical results can lower a product’s expected value, much like a road test predicts a car’s performance.

dermatology medical

"deployment across dermatology, oncology, and inflammatory disease programs"

Dermatology is the medical specialty focused on the diagnosis and treatment of conditions affecting the skin, hair and nails, including rashes, infections, chronic diseases and cosmetic concerns. It matters to investors because breakthroughs, approved treatments, new devices or shifts in care demand can change revenue prospects for drugmakers, device makers and clinics—think of it like weather changes that reshape a farmer’s crop yields, where regulatory approvals and patient demand drive financial outcomes.

oncology medical

"deployment across dermatology, oncology, and inflammatory disease programs"

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

inflammatory disease medical

"deployment across dermatology, oncology, and inflammatory disease programs"

A medical condition in which the body’s immune response causes ongoing or repeated swelling, pain and tissue damage in a specific area or throughout the body, like an overactive sprinkler system that keeps soaking a room and wearing it down. Investors watch inflammatory diseases because they drive demand for drugs, medical devices and tests, shape clinical trial outcomes and regulatory risk, and can create large, long‑term markets or cost liabilities for healthcare companies.

computational platform technical

"an advanced AI-enabled computational platform designed to accelerate drug discovery"

A computational platform is the combined set of software, hardware and tools a company uses to collect, store and process large amounts of data and run models or applications — like a factory floor where raw materials (data) are turned into finished products (insights, predictions or services). For investors, the platform’s speed, reliability and scale matter because they shape a company’s ability to launch features, cut costs, serve customers and create new revenue streams, which influence growth and risk.

AI-enabled technical

"an advanced AI-enabled computational platform designed to accelerate drug discovery"

AI-enabled describes a product, service, or process that uses artificial intelligence—software that learns from data and makes decisions or predictions—as a core feature rather than a minor add-on. For investors it matters because AI-enabled offerings can boost productivity, lower costs or unlock new revenue streams; like adding a smart autopilot to a routine task, they can change a company's growth potential and competitive edge while also bringing higher upfront investment needs and distinct regulatory or ethical risks.

AI-generated analysis. Not financial advice.

NEW YORK, March 26, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced the deployment of OpenClaw™, an advanced AI-enabled computational platform designed to accelerate drug discovery, enhance data-driven decision-making, and unlock value across its therapeutic pipeline.

OpenClaw™ Activation Marks Strategic Shift Toward AI-Driven Drug Development

The launch of OpenClaw™ establishes a centralized, high-performance platform capable of integrating preclinical and clinical datasets in real time, enabling faster and more efficient research execution.

Platform Designed to Accelerate Timelines and Increase Probability of Success

OpenClaw™ enables rapid analysis of complex biological data, supporting smarter candidate selection and prioritization. The platform is expected to enhance development efficiency and improve the probability of technical success across Hoth's programs.

Eliminating Data Silos While Scaling Across Multiple Indications

The system's modular design allows seamless deployment across dermatology, oncology, and inflammatory disease programs, standardizing workflows and increasing reproducibility at scale.

AI + Infrastructure Strategy Positions Hoth for Next Phase of Growth

With the deployment of OpenClaw™, Hoth strengthens its positioning at the intersection of biotechnology and artificial intelligence—leveraging advanced analytics to drive innovation and pipeline expansion.

"We are entering a new phase of execution at Hoth," said Robb Knie, Chief Executive Officer. "OpenClaw™ enhances our ability to move faster, make better decisions, and extract more value from our data—positioning us to accelerate."

About Hoth Therapeutics, Inc.

Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .

Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791

View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-deploys-openclaw-ai-platform-to-accelerate-drug-discovery-302725506.html

SOURCE Hoth Therapeutics, Inc.

FAQ

What is OpenClaw™ and how will it affect Hoth Therapeutics (HOTH)?

OpenClaw™ is an AI-enabled computational platform meant to centralize and analyze data for faster decisions. According to the company, it integrates preclinical and clinical datasets in real time to support candidate selection, standardize workflows, and accelerate development across multiple indications.

Which Hoth Therapeutics programs will use OpenClaw™ and when will it be deployed?

OpenClaw™ will be deployed across dermatology, oncology and inflammatory disease programs. According to the company, the platform’s modular design allows immediate scaling and standardized workflows across those programs to improve reproducibility and research execution.

How does OpenClaw™ claim to improve probability of success for Hoth (HOTH) drug candidates?

The platform enables rapid analysis of complex biological data to support smarter candidate selection and prioritization. According to the company, this data-driven approach is expected to enhance development efficiency and increase the probability of technical success across programs.

Will OpenClaw™ eliminate data silos at Hoth Therapeutics (HOTH)?

Yes, OpenClaw™ is designed to eliminate data silos by centralizing datasets and standardizing workflows. According to the company, real-time integration of preclinical and clinical data improves reproducibility and enables more efficient, cross-program analytics.

Does OpenClaw™ reflect a strategic shift for Hoth Therapeutics (HOTH)?

Hoth describes OpenClaw™ as a strategic move toward AI-driven drug development and pipeline expansion. According to the company, combining AI and infrastructure positions Hoth at the intersection of biotechnology and advanced analytics for future growth.

What operational benefits does Hoth expect from deploying OpenClaw™?

Hoth expects faster research execution, standardized workflows and improved reproducibility across programs. According to the company, the platform enables real-time data integration and rapid analysis, which should support quicker decisions and more efficient development processes.